Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California. Show more

One Letterman Drive, San Francisco, CA, 94129, United States

Biotechnology

Healthcare

Market Cap

2.253B

52 Wk Range

$24.31 - $32.00

Previous Close

$25.02

Open

$25.41

Volume

829,354

Day Range

$23.42 - $25.41

Enterprise Value

2.134B

Cash

122.8M

Avg Qtr Burn

-16.95M

Insider Ownership

58.16%

Institutional Own.

19.14%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BHB-1893 Details Symptomatic nHCM without significant LVOT obstruction	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHB-1893 Details Adults with symptomatic oHCM, including NYHA Class II–III patients	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.